- Home
- NPCE vs VALN Comparison
NPCE vs VALN Comparison
Compare NPCE & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- VALN
- Stock Information
- Founded
- NPCE 1997
- VALN 2012
- Country
- NPCE United States
- VALN France
- Employees
- NPCE N/A
- VALN N/A
- Industry
- NPCE Medical Specialities
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NPCE Health Care
- VALN Health Care
- Exchange
- NPCE Nasdaq
- VALN Nasdaq
- Market Cap
- NPCE 355.5M
- VALN 345.2M
- IPO Year
- NPCE 2021
- VALN 2021
- Fundamental
- Price
- NPCE $11.97
- VALN $4.36
- Analyst Decision
- NPCE Buy
- VALN Strong Buy
- Analyst Count
- NPCE 6
- VALN 2
- Target Price
- NPCE $15.83
- VALN $18.50
- AVG Volume (30 Days)
- NPCE 86.9K
- VALN 68.4K
- Earning Date
- NPCE 03-04-2025
- VALN 11-07-2024
- Dividend Yield
- NPCE N/A
- VALN N/A
- EPS Growth
- NPCE N/A
- VALN N/A
- EPS
- NPCE N/A
- VALN N/A
- Revenue
- NPCE $76,452,000.00
- VALN $176,817,979.00
- Revenue This Year
- NPCE $23.46
- VALN $24.66
- Revenue Next Year
- NPCE $14.64
- VALN $9.67
- P/E Ratio
- NPCE N/A
- VALN N/A
- Revenue Growth
- NPCE 27.00
- VALN N/A
- 52 Week Low
- NPCE $5.45
- VALN $3.62
- 52 Week High
- NPCE $18.15
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- NPCE 58.55
- VALN 48.76
- Support Level
- NPCE $11.37
- VALN $4.22
- Resistance Level
- NPCE $12.65
- VALN $4.51
- Average True Range (ATR)
- NPCE 0.96
- VALN 0.21
- MACD
- NPCE -0.05
- VALN 0.00
- Stochastic Oscillator
- NPCE 48.94
- VALN 41.90
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.